

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>

October 1st, 2023

Yasushi Tanoue appointed Chief Medical Officer (CMO)

Kanagawa, Japan, October 1st, 2023 – Chordia Therapeutics Inc. (“Chordia”), is pleased to announce the appointment of Dr. Yasushi Tanoue as Chief Medical Officer (“CMO”), effective September 15, 2023. With the appointment of Dr. Tanoue, the Company will further strengthen its management structure and move forward with developing new anti-cancer drugs.

Profile of Yasushi Tanoue, CMO

Yasushi Tanoue	Apr 2003	Worked at the University of Tokyo Hospital and affiliated medical facilities as a physician
	Aug 2017	Associate Director, Oncology Scientific Affairs, Oncology Science Unit, MSD K.K.
	Jan 2019	Head of MA Immuno-Oncology Japan, Medical Department, Merck Biopharma Co. Ltd.
	Feb 2020	Medical Director of Japan & Asia Clinical Development, Medicine Creation – Clinical, Oncology Business Group, Eisai Co., Ltd.
	Oct 2021	Senior Medical Director, Chordia Therapeutics Inc.

Comment from Hiroshi Miyake, CEO

We are delighted with the appointment of Yasushi Tanoue, MD, PhD. to CMO. As a medical expert, Dr. Tanoue has been involved in clinical development of novel cancer drugs in global pharmaceutical companies. I am confident that Dr. Tanoue, as the CMO, will further strengthen our clinical development team and accelerate the development of CTX-712.

Comment from Yasushi Tanoue, CMO

I am honored and extremely grateful to be appointed Chief Medical Officer of Chordia Therapeutics. I look forward to bringing my experience in clinical development to deliver innovative treatments to cancer patients as quickly and as effectively as possible.

About Chordia Therapeutics

Chordia was established in November 2017 at Shonan Health Innovation Park (“Shonan iPark”) in Fujisawa, Kanagawa Prefecture, as a biotech company engaged in the research and development of novel therapies for cancers, with the goal of researching and developing first-in-class anti-cancer drugs and creating innovative new drugs.

Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan

ir@chorditherapeutics.com



In addition to its leading program for CTX-712, Chordia is engaged in the research of several developments in our pipeline, including CTX-439, a CDK12 inhibitor, which is expected to be effective in cancers with specific abnormalities, as well as GCN2 inhibitors.

Established: November 2017
Address: 26-1, Muraoka-Higashi 2-chome, Fujisawa,
Kanagawa 251-0012, Japan
Representative: Hiroshi Miyake, Representative Director
Website: <https://www.chorditherapeutics.com/en/>

For more information, contact, IR Mizobe: ir@chorditherapeutics.com